Get the Stockscreener App
50.15
1.01%
0.50
After Hours:
49.70
-0.45
-0.90%
Exelixis Inc stock is traded at $50.15, with a volume of 1.54M.
It is up +1.01% in the last 24 hours and up +7.04% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$49.65
Open:
$49.75
24h Volume:
1.54M
Relative Volume:
0.56
Market Cap:
$12.61B
Revenue:
$2.32B
Net Income/Loss:
$782.57M
P/E Ratio:
18.01
EPS:
2.7838
Net Cash Flow:
$875.84M
1W Performance:
+0.04%
1M Performance:
+7.04%
6M Performance:
+17.97%
1Y Performance:
+17.01%
1-Day Range:
$49.51
$50.33
1-Week Range:
$48.21
$50.53
52-Week Range:
$33.76
$51.63
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
50.15 | 12.48B | 2.32B | 782.57M | 875.84M | 2.7838 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-21-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-19-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Initiated | Goldman | Buy |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Avoiding Lag: Real-Time Signals in (EXEL) Movement - Stock Traders Daily
Exelixis: Financial Performance Improves Faster Than Market Expectations (NASDAQ:EXEL) - Seeking Alpha
Exelixis EVP Patrick J. Haley sells $1.6m stock, prices $49.80 to $49.89 - Investing.com India
Exelixis Eyes CABO Growth as Zanzalintinib Readouts and Potential CRC Launch Near - Barchart.com
Insider Sell: Patrick Haley Sells 32,110 Shares of Exelixis Inc (EXEL) - GuruFocus
Exelixis EVP Patrick J. Haley sells $1.6m stock, prices $49.80 to $49.89 By Investing.com - Investing.com South Africa
Exelixis EVP, Commercial Sold Shares Worth Over $1.5M - TradingView
Exelixis (EXEL) EVP Haley sells 32,110 shares, retains 357,638 - Stock Titan
Exelixis (EXEL): 12 Best Low Priced Growth Stocks to Invest In Now - Insider Monkey
How Investors May Respond To Exelixis (EXEL) Merck MRD+ Colorectal Cancer Trial Collaboration - Sahm
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types - BioSpace
Exelixis Inc stock (US30161Q1040): oncology player in focus after latest earnings and pipeline updat - AD HOC NEWS
Assessing Exelixis (EXEL) Valuation After Merck Zanzalintinib Keytruda Colorectal Cancer Collaboration - Yahoo Finance
EXEL News | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Is Exelixis Stock Utilizing Systematic Share Retirement for Long-Term Alpha? - Trefis
EXEL (EXEL) Rule 144 filing: 32,110 issuer-held shares vested - Stock Titan
EXEL: Zanzalintinib targets leadership in CRC and RCC with pivotal trials and robust clinical strategy - TradingView
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study - TradingView
Exelixis Insider Sold Shares Worth $1,745,050, According to a Recent SEC Filing - Moomoo
Exelixis EVP and CFO Senner sells $1.75m in company stock By Investing.com - Investing.com South Africa
Exelixis EVP and CFO Senner sells $1.75m in company stock - Investing.com UK
Exelixis SVP Brenda Hefti sells $332,641 in stock - Investing.com UK
Exelixis SVP Brenda Hefti sells $332,641 in stock By Investing.com - Investing.com South Africa
Exelixis (NASDAQ: EXEL) CEO reports share gifts and tax withholding - Stock Titan
Exelixis (NASDAQ: EXEL) CFO sells shares, reports tax withholding and large remaining stake - Stock Titan
Exelixis (EXEL) EVP reports 33,265-share tax withholding, 389,748-share stake - Stock Titan
Insider sale: Exelixis (EXEL) SVP and General Counsel sells 6,625 shares - Stock Titan
Exelixis (NASDAQ: EXEL) EVP Dana Aftab reports tax-withholding of 30,578 shares - Stock Titan
Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial - Moomoo
Exelixis partners with Merck for colorectal cancer trial By Investing.com - Investing.com South Africa
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer - BioSpace
Merck (MRK) Partners with Exelixis in Clinical Trial for Colorec - GuruFocus
Exelixis partners with Merck for colorectal cancer trial - Investing.com
EXEL Stock Chart | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Proposed resale of vested restricted shares by EXEL (NASDAQ: EXEL) - Stock Titan
[144] EXELIXIS, INC. SEC Filing - Stock Titan
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating Growth Prospects Amidst Analyst Divergence - DirectorsTalk Interviews
Exelixis, Inc.Common Stock (NQ: EXEL - The Chronicle-Journal
Stephens Investment Management Group LLC Buys 28,265 Shares of Exelixis, Inc. $EXEL - MarketBeat
Thrivent Financial for Lutherans Increases Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis stock (US30161Q1040): New data and pipeline catalysts in focus - AD HOC NEWS
Prediction: This stock could double by 2031 - MSN
48,292 Shares in Exelixis, Inc. $EXEL Purchased by Convergence Investment Partners LLC - MarketBeat
Prediction: This Stock Could Double By 2031 - Yahoo Finance
Prediction: This Stock Could Double By 2031 - The Motley Fool
Exelixis (EXEL) is a Top-Ranked Momentum Stock: Should You Buy? - Yahoo Finance
Arbejdsmarkedets Tillaegspension Acquires Shares of 555,504 Exelixis, Inc. $EXEL - MarketBeat
Ameritas Advisory Services LLC Purchases Shares of 34,270 Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):